• HOME >
  • IBL News >
  • Cilostazol May Decrease Plasma Inflammatory Biomarkers in Patients with Recent Small Subcortical Infarcts: A Pilot Study

IBL News

Product News

Product News2018/12/12
Cilostazol May Decrease Plasma Inflammatory Biomarkers in Patients with Recent Small Subcortical Infarcts: A Pilot Study

Since the products introduced in the following IBL news are research use reagents, they can NOT be used for "diagnosis nor any medical purpose".

Naoki Saji, MD, PhD, vice head of Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology ( Obu, Aichi, JAPAN), et al revealed in a pilot study that evaluated 41 patients with stroke due to recent small subcortical infarcts divided into 2 groups according to the use of antiplatelet agents (cilostazol with or without aspirin versus aspirin alone) in the association with progressive neurological deficit and poor functional outcome and measured plasma inflammatory biomarkers that 1) plasma MMP-9 and high sensitive CRP were higher in patients with progressive neurological deficit and 2) plasma APP770 was more likely to be decreased in cilostazol group.

Cilostazol May Decrease Plasma Inflammatory Biomarkers in Patients with Recent Small Subcortical Infarcts: A Pilot Study. Saji N et al. J Stroke Cerebrovasc Dis. 2018 Jun;27(6):1639-1645. PMID: 29454567

(Background) 
Cerebral small-vessel diseases (SVD) are drawing attentions as risk factors for both stroke and cognitive decline. Among them recent small subcortical infarcts (RSSI, formerly defined as acute lacunar infarcts or Branch atheromatous disease) is a risk factor of both progressive neurological deficit (PND) and recurrent ischemic stroke. PND is a state of neurological worsening during a few days after the onset of stroke, which could lead to poor stroke outcome and is identified as a risk to further develop dementia.

Several studies suggested cilostazol with its antiplatelet and anti-inflammatory effect may prevent PND in patients with noncardioembolic stroke, in particular in those with RSSI. However the preventing mechanism of cilostazol to PND and relationship to plasma inflammatory biomarkers were so far not fully clarified. APP770 is a biomarker recently reported for endothelial dysfunction and cognitive decline. The result from this pilot study that plasma APP770 was decreased in cilostazol group is of interest, to think stroke relates to dementia.

As higher plasma APP770 is a possible indicator of intracranial microvascular amyloidβdeposition, the contributing effect of cilostazol on preventing to develop dementia after stroke is discussed in this study.

#27736 Human APP770 Assay Kit - IBL was used in this study.

We have also a comprehensive product lineup in Alzheimer’s disease.

Product Search

We hope that we can support your research.
Please feel free to
 contact us.

Sales Department
Diagnostic and Research Reagents Division
Immuno-Biological Laboratories Co., Ltd.
TEL: +81-274-50-8666
Email:
 do-ibl@ibl-japan.co.jp